Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Idasanutlin with Chemotherapy in Newly Diagnosed AML
NCT03850535Phase 2Terminated
- Sponsor
- Roche
- Start
- Mar 2019
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label trial of idasanutlin in acute myeloid leukemia (AML) (4 arms), sponsored by Roche. Primary endpoints: Number of Participants With Dose-Limiting Toxicities at Cycle 1, Number of Participants With at Least One Adverse Event up to 2 years and 5 more. Started Mar 2019; status: terminated.
02
Drugs
idasanutlin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03850535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03850535.